Evotec And Arix Bridge Gap With Latest Cancer Funding

Arix Biosciences and Evotec AG have formed an academic partnership to accelerate research discoveries at the Fred Hutchison Cancer Research Center.

SC1805_Golden Gate Bridge_136918865_1200.jpg

The German biotech Evotec AG is to use its BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) model, an integrated fund and reward model, to form a new partnership withArix BioSciences PLC, LAB591. Together with the Fred Hutchinson Cancer Research Center, the three partners will jointly select promising research projects from the laboratories of the cancer research center, which is based in Seattle. The initial term of LAB591 is five years.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.